Google Drive

Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23

U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality

Download now

Click here if your download doesn"t start automatically

Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23

U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality

Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality

Cystic fibrosis (CF) is the second most common life-shortening, childhood-onset genetic disease in the United States, affecting approximately 30,000 people in the Nation. The gene responsible for CF encodes the cystic fibrosis transmembrane regulator (CFTR) protein, which regulates sodium and chloride transport across epithelial membranes. This affects nearly all exocrine glands, with abnormally viscous mucus and excessive secretions. The dominant clinical features are chronic lung disease and pancreatic insufficiency with poor nutrition and growth. Treatment advances in CF over the past 25 years have improved measures of nutrition, pulmonary function, and mortality. Growth and nutritional indexes may be predictive of future pulmonary function in children with CF. It has been suggested that improvement of linear growth in children with CF may allow more lung mass and better pulmonary function, independent of improved weight gain. Both poor weight and shorter height have also been shown to be independently associated with increased morbidity and mortality in CF patients in some studies. Recombinant human growth hormone (rhGH) is an anabolic agent with a wide variety of actions. It has been investigated for the treatment of CF because of the decreased growth measures and increased energy expenditures in CF patients. This Review, prepared by the University of Connecticut/Hartford Hospital Evidence-based Practice Center (EPC), examines the benefits and harms associated with using rhGH in patients with CF. The key questions examined are: KQ 1: In patients with CF, does treatment with rhGH as an adjuvant to usual care improve intermediate outcomes, including pulmonary function; growth (height, weight, lean body mass [LBM], protein turnover), exercise tolerance, and bone mineralization, compared with usual care alone? KQ 2: In patients with CF, does treatment with rhGH as an adjuvant to usual care improve health outcomes, including frequency of required intravenous antibiotic treatments, frequency of hospitalization; quality of life; bone fracture or development of osteoporosis/osteopenia, or mortality, compared with usual care alone? KQ 3: In patients with CF, what is the strength of evidence that intermediate outcomes of pulmonary function, growth, and bone mineralization are associated with improvements in health outcomes of quality of life, bone fracture or development of osteoporosis/osteopenia, or mortality? KQ: In patients with CF, what is the frequency of nonmalignant serious adverse effects resulting from treatment with rhGH? Adverse effects of interest include, but are not limited to, glucose intolerance, diabetes, and hypoglycemia. KQ 5: What is the risk of malignancy associated with rhGH use as determined by: (a) markers of cancer risk with rhGH (insulin-like growth factor-I [IGF-I] increases over 100 ng/ml or insulin-like growth factor binding protein-3[(IGFBP-3] decreases over 1,000 ng/ml) from studies of rhGH in people with CF and by (b) assessment of evidence on cancer incidence from non-CF patients receiving modest doses of rhGH (0.2 mg/kg/week to 0.6 mg/kg/week) for disorders such as growth hormone deficiency (GHD) and idiopathic short stature (ISS)? KQ 6: In patients with CF, how are efficacy, effectiveness, safety, or adverse events impacted by rhGH dose, therapy duration, baseline nutritional status, and concurrent medical therapies? KQ 7: In patients with CF, how do the efficacy, effectiveness, safety, or adverse events of treatment with rhGH differ between subgroups of patients? Subgroup characteristics of interest include, but are not limited to, age (prepubertal, pubertal, postpubertal), gender, baseline clinical status (height, weight, LBM, pulmonary function, exercise tolerance, nutritional status), and/or the nature, extent, and effectiveness of prior treatment.

Download Effectiveness of Recombinant Human Growth Hormone ...pdf

Read Online Effectiveness of Recombinant Human Growth Hormon ...pdf

Download and Read Free Online Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality

---

From reader reviews:

Araceli Burns:

Reading a book tends to be new life style in this particular era globalization. With reading you can get a lot of information that will give you benefit in your life. With book everyone in this world may share their idea. Publications can also inspire a lot of people. A great deal of author can inspire their very own reader with their story or maybe their experience. Not only the storyplot that share in the ebooks. But also they write about the information about something that you need case in point. How to get the good score toefl, or how to teach your young ones, there are many kinds of book which exist now. The authors on this planet always try to improve their talent in writing, they also doing some exploration before they write to their book. One of them is this Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23.

Tammy Medina:

Exactly why? Because this Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 is an unordinary book that the inside of the reserve waiting for you to snap that but latter it will shock you with the secret this inside. Reading this book alongside it was fantastic author who write the book in such wonderful way makes the content inside easier to understand, entertaining way but still convey the meaning entirely. So , it is good for you for not hesitating having this any more or you going to regret it. This amazing book will give you a lot of positive aspects than the other book get such as help improving your talent and your critical thinking way. So , still want to postpone having that book? If I ended up you I will go to the book store hurriedly.

Sunny Weaver:

Do you have something that you enjoy such as book? The book lovers usually prefer to pick book like comic, brief story and the biggest one is novel. Now, why not hoping Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 that give your fun preference will be satisfied through reading this book. Reading addiction all over the world can be said as the opportunity for people to know world considerably better then how they react to the world. It can't be claimed constantly that reading practice only for the geeky man but for all of you who wants to become success person. So , for all you who want to start studying as your good habit, you could pick Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 become your starter.

Robert Vargas:

Your reading 6th sense will not betray a person, why because this Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness

Review Number 23 e-book written by well-known writer who really knows well how to make book which can be understand by anyone who also read the book. Written throughout good manner for you, dripping every ideas and producing skill only for eliminate your own hunger then you still uncertainty Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 as good book not just by the cover but also from the content. This is one book that can break don't evaluate book by its include, so do you still needing another sixth sense to pick this!? Oh come on your looking at sixth sense already told you so why you have to listening to another sixth sense.

Download and Read Online Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality #JC86S0XTGEH

Read Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality for online ebook

Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality Free PDF d0wnl0ad, audio books, books to read, good books to read, cheap books, good books, online books, books online, book reviews epub, read books online, books to read online, online library, greatbooks to read, PDF best books to read, top books to read Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality books to read online.

Online Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality ebook PDF download

Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality Doc

Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality Mobipocket

Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis: Comparative Effectiveness Review Number 23 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality EPub